ECONOMIC OUTCOMES AND REAL-WORLD ADHERENCE OF PATIENTS WITH SICKLE CELL DISEASE WITH RECURRENT VASO-OCCLUSIVE CRISES TREATED WITH L-GLUTAMINE, VOXELOTOR, AND CRIZANLIZUMAB IN THE UNITED STATES

被引：0
|
作者：
Udeze, C. [1 ]
Jerry, M. [2 ]
Evans, K. [2 ]
Li, N. [1 ]
Jain, S. [1 ]
Andemariam, B. [3 ]
机构：
[1] Vertex Pharmaceut Inc, Boston, MA USA
[2] Merative, Ann Arbor, MI USA
[3] Univ Connecticut Hlth, Farmington, CT USA
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE132
引用
收藏
页码：S81 / S81
页数：1
相关论文
共 50 条
  • [1] Comparing the Safety and Efficacy of L-Glutamine, Voxelotor, and Crizanlizumab for Reducing the Frequency of Vaso-Occlusive Crisis in Sickle Cell Disease: A Systematic Review
    Dick, Maurice H.
    Abdelgadir, Arowa
    Kulkarni, Vaishnavi Vijaya
    Akram, Hamna
    Chatterjee, Abanti
    Pokhrel, Sushil
    Khan, Safeera
    [J]. CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (05)
  • [2] Crizanlizumab approved in Europe for Prevention of recurrent vaso-occlusive Crises in Sickle Cell Disease
    不详
    [J]. TRANSFUSION MEDICINE AND HEMOTHERAPY, 2021, 48 (01) : 69 - 69
  • [3] Economic and Clinical Burden of Managing Sickle Cell Disease with Recurrent Vaso-Occlusive Crises in the United States
    Chuka Udeze
    Kristin A. Evans
    Yoojung Yang
    Timothy Lillehaugen
    Janna Manjelievskaia
    Urvi Mujumdar
    Nanxin Li
    Biree Andemariam
    [J]. Advances in Therapy, 2023, 40 : 3543 - 3558
  • [4] Economic and Clinical Burden of Managing Sickle Cell Disease with Recurrent Vaso-Occlusive Crises in the United States
    Udeze, Chuka
    Evans, Kristin A.
    Yang, Yoojung
    Lillehaugen, Timothy
    Manjelievskaia, Janna
    Mujumdar, Urvi
    Li, Nanxin
    Andemariam, Biree
    [J]. ADVANCES IN THERAPY, 2023, 40 (08) : 3543 - 3558
  • [5] Real-World Outcomes in Adult Sickle Cell Disease Patients Treated with Crizanlizumab, Voxelotor or Both
    Etti, Abisola Baruwa
    Kuo, Chia-ling
    Godoy, Lucas Da Cunha
    Andemariam, Biree
    [J]. BLOOD, 2022, 140 : 8292 - 8293
  • [6] Correction to: Economic and Clinical Burden of Managing Sickle Cell Disease with Recurrent Vaso-Occlusive Crises in the United States
    Chuka Udeze
    Kristin A. Evans
    Yoojung Yang
    Timothy Lillehaugen
    Janna Manjelievskaia
    Urvi Mujumdar
    Nanxin Li
    Biree Andemariam
    [J]. Advances in Therapy, 2023, 40 : 5130 - 5130
  • [7] The European Medicines Agency Review of Crizanlizumab for the Prevention of Recurrent Vaso-Occlusive Crises in Patients With Sickle Cell Disease
    Delgado, Julio
    Voltz, Caroline
    Stain, Milena
    Lapvetelainen, Tuomo
    Urach, Susanne
    Lahteenvuo, Johanna
    Penttila, Karri
    Gisselbrecht, Christian
    Enzmann, Harald
    Pignatti, Francesco
    [J]. HEMASPHERE, 2021, 5 (07): : E604
  • [8] MODELLING LONG-TERM CLINICAL OUTCOMES OF PATIENTS WITH SICKLE CELL DISEASE WITH RECURRENT VASO-OCCLUSIVE CRISES IN THE UNITED STATES
    Wang, J.
    Udeze, C.
    Ogunsile, F. J.
    Xie, Y.
    Mujumdar, U.
    Yang, H.
    Salcedo, J.
    Lopez, A.
    [J]. VALUE IN HEALTH, 2022, 25 (12) : S91 - S91
  • [9] Systematic Review of l-glutamine for Prevention of Vaso-occlusive Pain Crisis in Patients with Sickle Cell Disease
    Cieri-Hutcherson, Nicole E.
    Hutcherson, Timothy C.
    Conway-Habes, Erin E.
    Burns, Brianna N.
    White, Nathan A.
    [J]. PHARMACOTHERAPY, 2019, 39 (11): : 1095 - 1104
  • [10] Real-World Effectiveness of Voxelotor for the Treatment of Sickle Cell Disease: Group and Pediatric Subgroup Analyses of Effects on Transfusions, Vaso-Occlusive Crises, and Hospitalizations
    Shah, Nirmish
    Lipato, Thokozeni
    Delea, Thomas E.
    Lonshteyn, Alexander
    Weycker, Derek
    Nguyen, Andy
    Beaubrun, Anne
    Alvarez, Ofelia A.
    [J]. BLOOD, 2022, 140 : 1954 - 1956
12345